A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation

Documenti analoghi

• Clinical outcomes with olanzapine long-acting injection: impact of the 3-hour observation period on patient satisfaction and well-being
  di: Anand, Ernie, et al.
  Pubblicazione: (2016)
• Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses
  di: Ciudad, Antonio, et al.
  Pubblicazione: (2013)
• Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons
  di: Ascher-Svanum, Haya, et al.
  Pubblicazione: (2012)
• A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection
  di: Atkins, Susan, et al.
  Pubblicazione: (2014)
• Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study
  di: McDonnell, David P., et al.
  Pubblicazione: (2014)